FibroGen (STU:1FG) Ending Cash Position : €130.7 Mil (As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is FibroGen Ending Cash Position?

FibroGen's Ending Cash Position for the quarter that ended in Jun. 2024 was €130.7 Mil.

FibroGen's quarterly Ending Cash Position declined from Dec. 2023 (€104.3 Mil) to Mar. 2024 (€97.3 Mil) but then increased from Mar. 2024 (€97.3 Mil) to Jun. 2024 (€130.7 Mil).

FibroGen's annual Ending Cash Position declined from Dec. 2021 (€151.5 Mil) to Dec. 2022 (€147.0 Mil) and declined from Dec. 2022 (€147.0 Mil) to Dec. 2023 (€104.3 Mil).

FibroGen Ending Cash Position Historical Data

The historical data trend for FibroGen's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen Ending Cash Position Chart

FibroGen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

113.64

557.64

151.53

146.98

104.25

FibroGen Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Ending Cash Position	Get a 7-Day Free Trial															140.84	113.30	104.25	97.28	130.72

FibroGen Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

FibroGen's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	142.777	+	-38.525
	=	104.3

FibroGen's Ending Cash Position for the quarter that ended in Jun. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	98.226	+	32.497
	=	130.7

FibroGen Ending Cash Position Related Terms

Thank you for viewing the detailed overview of FibroGen's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

FibroGen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (STU:1FG) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

FGEN:USA FGEN:Mexico 0IL8:UK

Address

409 Illinois Street, San Francisco, CA, USA, 94158

Website

https://www.fibrogen.com

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

FibroGen Headlines

No Headlines